Literature DB >> 21086074

Stroke prevention treatment of patients with atrial fibrillation: old and new.

Simerpreet Bal1, Pawan Ojha, Michael D Hill.   

Abstract

Atrial fibrillation is the most common cause of cardioembolic ischemic stroke and has a rising prevalence worldwide. Stroke prevention in this condition is poised to take a substantial leap forward with the evolution of new anticoagulant medications, with superior properties compared to vitamin K antagonists. New, safer and more effective chronic therapy is on the horizon. However, many issues surrounding the management of stroke prevention after an acute stroke and during the course of chronic anticoagulant therapy remain to be resolved.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21086074     DOI： 10.1007/s11910-010-0161-z

Source DB:  PubMed          Journal:  Curr Neurol Neurosci Rep        ISSN： 1528-4042            Impact factor:   5.081


  104 in total

1.  Fibrinogen and fibrin D-dimer levels in paroxysmal atrial fibrillation: evidence for intermediate elevated levels of intravascular thrombogenesis.

Authors:  G Y Lip; G D Lowe; A Rumley; F G Dunn
Journal:  Am Heart J       Date:  1996-04       Impact factor: 4.749

2.  Increased von Willebrand factor in the endocardium as a local predisposing factor for thrombogenesis in overloaded human atrial appendage.

Authors:  M Fukuchi; J Watanabe; K Kumagai; Y Katori; S Baba; K Fukuda; T Yagi; A Iguchi; H Yokoyama; M Miura; Y Kagaya; S Sato; K Tabayashi; K Shirato
Journal:  J Am Coll Cardiol       Date:  2001-04       Impact factor: 24.094

3.  Prognostic significance of raised plasma levels of interleukin-6 and C-reactive protein in atrial fibrillation.

Authors:  Dwayne S g Conway; Peter Buggins; Elizabeth Hughes; Gregory Y H Lip
Journal:  Am Heart J       Date:  2004-09       Impact factor: 4.749

4.  Effect of dronedarone on cardiovascular events in atrial fibrillation.

Authors:  Stefan H Hohnloser; Harry J G M Crijns; Martin van Eickels; Christophe Gaudin; Richard L Page; Christian Torp-Pedersen; Stuart J Connolly
Journal:  N Engl J Med       Date:  2009-02-12       Impact factor: 91.245

Review 5.  Comparison of 12 risk stratification schemes to predict stroke in patients with nonvalvular atrial fibrillation.

Authors: 
Journal:  Stroke       Date:  2008-04-17       Impact factor: 7.914

6.  Randomized, prospective trial comparing bridging therapy using low-molecular-weight heparin with maintenance of oral anticoagulation during extraction of teeth.

Authors:  Branislav V Bajkin; Stevan L Popovic; Srecko D J Selakovic
Journal:  J Oral Maxillofac Surg       Date:  2009-05       Impact factor: 1.895

7.  Effects of the synthetic thrombin inhibitor argatroban on fibrin- or clot-incorporated thrombin: comparison with heparin and recombinant Hirudin.

Authors:  C N Berry; C Girardot; C Lecoffre; C Lunven
Journal:  Thromb Haemost       Date:  1994-09       Impact factor: 5.249

8.  The structure of a complex of recombinant hirudin and human alpha-thrombin.

Authors:  T J Rydel; K G Ravichandran; A Tulinsky; W Bode; R Huber; C Roitsch; J W Fenton
Journal:  Science       Date:  1990-07-20       Impact factor: 47.728

9.  The Cataract National Dataset electronic multicentre audit of 55,567 operations: antiplatelet and anticoagulant medications.

Authors:  J D Benzimra; R L Johnston; P Jaycock; P H Galloway; G Lambert; A K K Chung; T Eke; J M Sparrow
Journal:  Eye (Lond)       Date:  2008-02-08       Impact factor: 3.775

10.  Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial.

Authors:  Jonathan Mant; F D Richard Hobbs; Kate Fletcher; Andrea Roalfe; David Fitzmaurice; Gregory Y H Lip; Ellen Murray
Journal:  Lancet       Date:  2007-08-11       Impact factor: 79.321
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.